Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study

Robert SA 1 , Rohana AG 2 , Shah SA 3 , Chinna K 4 , Wan Mohamud WN 5 , Kamaruddin NA 6

Affiliations 

  • 1 Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. Electronic address: sarahrobert@ppukm.ukm.edu.my
  • 2 Faculty of Medicine, Universiti Teknologi Mara, Sungai Buloh, Selangor, Malaysia
  • 3 Department of Community Health, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • 4 Department of Social and Preventive Medicine, Faculty of Medicine Universiti Malaya, Kuala Lumpur, Malaysia
  • 5 Cardiovascular, Diabetes and Nutrition Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia
  • 6 Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
Obes Res Clin Pract, 2015 May-Jun;9(3):301-4.
PMID: 25870084 DOI: 10.1016/j.orcp.2015.03.005

Abstract

We examined the effects of liraglutide, a glucagon-like peptide-1 analogue on appetite and plasma ghrelin in non-diabetic obese participants with subclinical binge eating (BE). Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks. All participants received standard advice for diet and exercise. Binge eating score, ghrelin levels and other anthropometric variables were evaluated at baseline and at the end of the study. Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol. Ghrelin levels were significantly increased which may potentially diminish the weight loss effects of liraglutide beyond the intervention.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications